Table 1 Summary of baseline biomarker-defined subgroup efficacy at 24 weeks in the ADACTA trial
From: Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Biomarker subset, number | ADA ACR20 (%) | ADA ACR50 (%) | ADA ACR70 (%) | ADA ∆DAS28-ESR (±SE) | ACR50 odds ratio ADA versus TCZ (95% CI) |
|---|---|---|---|---|---|
sICAM1high/CXCL13low (26) | 73 | 42 | 23 | -2.3 (±0.37) | 2.93 (0.7-15.2) |
sICAM1low/CXCL13high (15) | 27 | 13 | 7 | -1.1 (±0.33) | 0.07 (0.009-0.3) |
sICAM1high/CXCL13high (32) | 50 | 28 | 19 | -2.1 (±0.31) | 0.53 (0.17-1.6) |
sICAM1low/CXCL13low (33) | 52 | 24 | 18 | -2.1 (±0.32) | 0.41 (0.13-1.2) |
Biomarker subset, number | TCZ ACR20 (%) | TCZ ACR50 (%) | TCZ ACR70 (%) | TCZ ∆DAS28-ESR (±SE) | ACR50 odds ratio TCZ vs. ADA (95% CI) |
sICAM1high/CXCL13low (15) | 60 | 20 | 7 | -3.2 (±0.37) | 0.34 (0.07-1.4) |
sICAM1low/CXCL13high (26) | 81 | 69 | 50 | -3.6 (±0.32) | 14.6 (3.1-108.9) |
sICAM1high/CXCL13high (26) | 58 | 42 | 31 | -3.2 (±0.37) | 1.9 (0.63-5.73) |
sICAM1low/CXCL13low (25) | 60 | 44 | 24 | -2.9 (±0.36) | 2.5 (0.8-7.8) |